Lexeo Therapeutics, Inc. Common Stock – NASDAQ:LXEO

Add to watchlist

$4.78

-2

-29.5%

Market closed

Open in about 12 hours

-61.48%

month

-61.48%

quarter

-57.38%

year

Market Cap	207.32M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-2.64

Revenue	N/A
EBITDA	-67.27M
Income	-69.41M
Revenue Q/Q	N/A
Revenue Y/Y	-100%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO): Profit margin
Jun 2023	0	-13.44M
Sep 2023	0	-20.10M
Dec 2023	0	-14.18M
Mar 2024	0	-21.68M

Lexeo Therapeutics, Inc. Common Stock Financials Estimate

Q Y

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO): Analyst Estimates
2025	642.86K	-91.05M	-14163.45%
2026	1.5M	-79.26M	-5284.44%

Analysts Price target
Financials & Ratios estimates

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO): Earnings per share (EPS)
2024-03-11	-0.71	-0.86
2024-05-09	-0.76	-0.77

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO): Debt to assets
Jun 2023	64939000	208.55M	321.16%
Sep 2023	54724000	217.53M	397.51%
Dec 2023	139807000	26.27M	18.79%
Mar 2024	213205000	30.25M	14.19%

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO): Cash Flow
Jun 2023	-13.19M	-39K	-94K
Sep 2023	-13.94M	-53K	3.91M
Dec 2023	-13.98M	-73K	100.07M
Mar 2024	-14.86M	-193K	88.65M

Lexeo Therapeutics, Inc. Common Stock alternative data

Lexeo Therapeutics, Inc. Common Stock
Employees

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO): Employee count
Mar 2024	58
Apr 2024	58
May 2024	58
Jun 2024	58
Jul 2024	58

Lexeo Therapeutics, Inc. Common Stock
Insider Trading

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO): Insider trades (number of shares)
Period	Buy	Sel
Sep 2024	0	5000
Oct 2024	0	5000
Nov 2024	15000	2500
Dec 2024	0	2500

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Option	10 Dec 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Common Stock	2,500	$2.33	$5,825
Sale	10 Dec 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Common Stock	2,500	$8.2	$20,492
Option	10 Dec 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Stock Option (right to buy)	2,500	$2.33	$5,825
Purchase	25 Nov 2024	CHOLMONDELEY PAULA H director director	Common Stock	15,000	$6.99	$104,850
Option	11 Nov 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Common Stock	2,500	$2.33	$5,825
Option	11 Nov 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Stock Option (right to buy)	2,500	$2.33	$5,825
Sale	11 Nov 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Common Stock	2,500	$7.82	$19,558
Option	10 Oct 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Common Stock	5,000	$2.33	$11,650
Option	10 Oct 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Stock Option (right to buy)	5,000	$2.33	$11,650
Sale	10 Oct 2024	TOWNSEND RICHARD NOLAN director, officer: Chief Executive .. director, officer: Chief Execut..	Common Stock	5,000	$8.1	$40,495

LXEO insider trading transactions

Lexeo Therapeutics, Inc. Common Stock
Latest News

Wednesday, 13 November 2024
07:30	Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results	globenewswire.com
Wednesday, 30 October 2024
06:14	Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference	globenewswire.com
Tuesday, 22 October 2024
07:30	Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference	globenewswire.com
Thursday, 5 September 2024
07:30	Lexeo Therapeutics to Participate in Upcoming Investor Conferences	globenewswire.com
Monday, 12 August 2024
07:00	Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights	globenewswire.com
Tuesday, 16 July 2024
13:17	Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further	seekingalpha.com
12:05	Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data	zacks.com
Monday, 15 July 2024
12:05	Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet	benzinga.com
06:00	Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy	globenewswire.com
Monday, 8 July 2024
07:00	Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors	globenewswire.com
Tuesday, 14 May 2024
13:01	What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock	Zacks Investment Research
10:56	Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet	Zacks Investment Research
Tuesday, 7 May 2024
07:30	Lexeo Therapeutics to Participate in Upcoming Investor Conferences	GlobeNewsWire
Tuesday, 9 April 2024
17:26	Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off	Seeking Alpha
Monday, 11 December 2023
12:05	LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023	InvestorPlace
Saturday, 4 November 2023
00:21	U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO	Seeking Alpha
Friday, 3 November 2023
12:39	Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range	Market Watch

Frequently Asked Questions (FAQ)

What's the price of Lexeo Therapeutics, Inc. Common Stock stock today?

One share of Lexeo Therapeutics, Inc. Common Stock stock can currently be purchased for approximately $4.78.
When is Lexeo Therapeutics, Inc. Common Stock's next earnings date?

Unfortunately, Lexeo Therapeutics, Inc. Common Stock's (LXEO) next earnings date is currently unknown.
Does Lexeo Therapeutics, Inc. Common Stock pay dividends?

No, Lexeo Therapeutics, Inc. Common Stock does not pay dividends.
How much money does Lexeo Therapeutics, Inc. Common Stock make?

Lexeo Therapeutics, Inc. Common Stock has a market capitalization of 207.32M. Lexeo Therapeutics, Inc. Common Stock made a loss 66.39M US dollars in net income (profit) last year or -$0.77 on an earnings per share basis.
What is Lexeo Therapeutics, Inc. Common Stock's stock symbol?

Lexeo Therapeutics, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "LXEO".
What is Lexeo Therapeutics, Inc. Common Stock's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Lexeo Therapeutics, Inc. Common Stock?

Shares of Lexeo Therapeutics, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Lexeo Therapeutics, Inc. Common Stock have?

As Jul 2024, Lexeo Therapeutics, Inc. Common Stock employs 58 workers.
When Lexeo Therapeutics, Inc. Common Stock went public?

Lexeo Therapeutics, Inc. Common Stock is publicly traded company for just a year since IPO on 3 Nov 2023.
What is Lexeo Therapeutics, Inc. Common Stock's official website?

The official website for Lexeo Therapeutics, Inc. Common Stock is lexeotx.com.
How can i contact Lexeo Therapeutics, Inc. Common Stock?

Lexeo Therapeutics, Inc. Common Stock can be reached via phone at +212 5479879.

Lexeo Therapeutics, Inc. Common Stock

lexeotx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

+212 5479879

345 Park Avenue South
New York, 10010

CIK: 0001907108
ISIN: US52886X1072
CUSIP: 52886X107